Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation
Circulation: Cardiovascular Interventions · 2025
DOI: 10.1161/circinterventions.125.015495 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025. Verfasst von Masahiro Natsuaki und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Saga University, Japan (M.N.). Hauptthemen laut MEDLINE: Clopidogrel, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Aspirin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: There were no previous studies comparing aspirin with clopidogrel on top of oral anticoagulation (OAC) within 1 year after percutaneous coronary intervention when dual therapy with OAC and clopidogrel was recommended. METHODS: We conducted a subgroup analysis stratified by OAC in the 1-year follow-up of the STOPDAPT-3 trial (Short and Optimal Duration of Dual Antiplatelet Therapy-3), which randomly compared 1-month dual antiplatelet therapy followed by aspirin monotherapy (aspirin group) with 1-month prasugrel monotherapy followed by clopidogrel monotherapy (clopidogrel group). This subgroup analysis compared aspirin with clopidogrel in patients with or without OAC by the 30-day landmark analysis. The coprimary end points were the cardiovascular (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke), and bleeding end points (Bleeding Academic Research Consortium 3 or 5). RESULTS: In the 30-day landmark analysis (N=5809), there were 788 patients (13.6%) with OAC at discharge. Regardless of OAC, the incidence rates beyond 30 days up to 1 year were similar between the aspirin and clopidogrel groups for cardiovascular end point (OAC: 3.7% versus 3.9%, hazard ratio, 0.92 [95% CI, 0.44–1.93]; no OAC: 3.7% versus 3.6%; hazard ratio, 1.03 [95% CI, 0.77–1.38]; P interaction=0.78) and for bleeding end point (OAC: 3.5% versus 4.2%, hazard ratio, 0.82 [95% CI, 0.39–1.73]; no OAC 1.5% versus 1.4%, hazard ratio, 1.07 [95% CI, 0.66–1.72]; P interaction=0.57). CONCLUSIONS: Aspirin compared with clopidogrel was associated with similar cardiovascular and bleeding outcomes beyond 30 days and up to 1 year after percutaneous coronary intervention regardless of OAC at discharge. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04609111.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Saga University, Japan (M.N.).
- Division of Cardiology, Hirakata Kohsai Hospital, Japan (H.W., H.T., Takeshi Kimura).
- Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan (T.M., Tomoya Kimura).
- Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan (K.Y., K.A.).
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y.O., R.N., K.O.).
- Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan (Tomoya Kimura).
ORCID-Profile: Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Tetsuya Ishikawa, Toshihiro Tamura, Fujio Hayashi, Masaharu Akao, Hiroyoshi Mori, Arata Hagikura, Naoki Shibata, Koh Ono, Takeshi Kimura
Zitieren
APA
Natsuaki, M., Watanabe, H., Morimoto, T., Yamamoto, K., Obayashi, Y., Nishikawa, R., Kimura, T., Ando, K., Suwa, S., Isawa, T., Takenaka, H., Ishikawa, T., Tamura, T., Kawahatsu, K., Hayashi, F., Akao, M., Serikawa, T., Mori, H., Kawamura, T., …, & Kimura, T. (2025). Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.015495
Vancouver
Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation. Circulation: Cardiovascular Interventions. 2025. doi:10.1161/circinterventions.125.015495
BibTeX
@article{Natsuaki2025,
author = {Natsuaki, Masahiro and Watanabe, Hirotoshi and Morimoto, Takeshi and Yamamoto, Ko and Obayashi, Yuki and Nishikawa, Ryusuke and Kimura, Tomoya and Ando, Kenji and Suwa, Satoru and Isawa, Tsuyoshi and Takenaka, Hiroyuki and Ishikawa, Tetsuya and Tamura, Toshihiro and Kawahatsu, Kandoh and Hayashi, Fujio and Akao, Masaharu and Serikawa, Takeshi and Mori, Hiroyoshi and Kawamura, Takayuki and Hagikura, Arata and Shibata, Naoki and Ono, Koh and Kimura, Takeshi},
title = {Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation},
journal = {Circulation: Cardiovascular Interventions},
year = {2025},
doi = {10.1161/circinterventions.125.015495}
}
EUVIMED